JP2008509149A - 造影剤の注入を受けるヒトの処置方法 - Google Patents

造影剤の注入を受けるヒトの処置方法 Download PDF

Info

Publication number
JP2008509149A
JP2008509149A JP2007524981A JP2007524981A JP2008509149A JP 2008509149 A JP2008509149 A JP 2008509149A JP 2007524981 A JP2007524981 A JP 2007524981A JP 2007524981 A JP2007524981 A JP 2007524981A JP 2008509149 A JP2008509149 A JP 2008509149A
Authority
JP
Japan
Prior art keywords
human
contrast agent
iron chelator
renal failure
iron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007524981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509149A5 (https=
Inventor
ブイ． シャー，スディア
Original Assignee
シバ バイオメディカル，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シバ バイオメディカル，エルエルシー filed Critical シバ バイオメディカル，エルエルシー
Publication of JP2008509149A publication Critical patent/JP2008509149A/ja
Publication of JP2008509149A5 publication Critical patent/JP2008509149A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
JP2007524981A 2004-08-06 2005-08-05 造影剤の注入を受けるヒトの処置方法 Pending JP2008509149A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59944904P 2004-08-06 2004-08-06
PCT/US2005/027712 WO2006017650A2 (en) 2004-08-06 2005-08-05 Iron chelators for treating radiocontrast-associated renal dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011274990A Division JP2012102110A (ja) 2004-08-06 2011-12-15 造影剤の注入を受けるヒトの処置方法

Publications (2)

Publication Number Publication Date
JP2008509149A true JP2008509149A (ja) 2008-03-27
JP2008509149A5 JP2008509149A5 (https=) 2011-02-24

Family

ID=35539425

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007524981A Pending JP2008509149A (ja) 2004-08-06 2005-08-05 造影剤の注入を受けるヒトの処置方法
JP2011274990A Withdrawn JP2012102110A (ja) 2004-08-06 2011-12-15 造影剤の注入を受けるヒトの処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011274990A Withdrawn JP2012102110A (ja) 2004-08-06 2011-12-15 造影剤の注入を受けるヒトの処置方法

Country Status (6)

Country Link
US (3) US20060127315A1 (https=)
EP (1) EP1776118A2 (https=)
JP (2) JP2008509149A (https=)
AU (1) AU2005271455A1 (https=)
CA (1) CA2576190A1 (https=)
WO (1) WO2006017650A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528207A (ja) * 2015-08-31 2018-09-27 ザ ユニバーシティー オブ アデレード 鉄キレート剤および非鉄ポルフィリンを含む、微生物感染症を予防および／または処置する方法および製品
JP2021500377A (ja) * 2017-10-25 2021-01-07 キエージ・フアルマチエウテイチ・エツセ・ピ・ア 遅延放出デフェリプロン錠剤及びその使用法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080004507A1 (en) * 2004-10-27 2008-01-03 E-Z-Em, Inc. Data collection device, system, method, and computer program product for collecting data related to the dispensing of contrast media
WO2008057534A2 (en) * 2006-11-07 2008-05-15 University Of Vermont And State Agricultural College Methods and compositions for organ protection
US20080138440A1 (en) * 2006-11-29 2008-06-12 Cormedix Inc. Methods of diagnosing and alleviating gadolinium toxicity
MX2017008959A (es) 2015-01-07 2018-05-17 Nottingham Univ Hospitals Nhs Trust Biomarcadores relacionados con la funcion del riñon y metodos que involucran su uso.
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543386A (ja) * 1999-04-23 2002-12-17 シヴァ バイオメディカル，エルエルシー ヒト腎臓疾患の診断

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1100388A (en) * 1986-12-29 1988-07-27 The Administrators Of The Tulane Eductional Fund Protection against aminoglycoside-induced nephrotoxicity
US5091180A (en) * 1987-11-20 1992-02-25 Administrators Of The Tulane Educational Fund Protection against rhabdomyolysis-induced nephrotoxicity
US6933104B1 (en) * 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
US6509380B1 (en) * 2001-12-14 2003-01-21 Marshall University Research Corporation Method of treating iron overload with acetaminophen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543386A (ja) * 1999-04-23 2002-12-17 シヴァ バイオメディカル，エルエルシー ヒト腎臓疾患の診断

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528207A (ja) * 2015-08-31 2018-09-27 ザ ユニバーシティー オブ アデレード 鉄キレート剤および非鉄ポルフィリンを含む、微生物感染症を予防および／または処置する方法および製品
JP2021500377A (ja) * 2017-10-25 2021-01-07 キエージ・フアルマチエウテイチ・エツセ・ピ・ア 遅延放出デフェリプロン錠剤及びその使用法
JP7246384B2 (ja) 2017-10-25 2023-03-27 キエージ・フアルマチエウテイチ・エツセ・ピ・ア 遅延放出デフェリプロン錠剤及びその使用法

Also Published As

Publication number Publication date
WO2006017650A3 (en) 2006-11-09
US20080293779A1 (en) 2008-11-27
US20120053212A1 (en) 2012-03-01
US20060127315A1 (en) 2006-06-15
AU2005271455A1 (en) 2006-02-16
WO2006017650A2 (en) 2006-02-16
EP1776118A2 (en) 2007-04-25
JP2012102110A (ja) 2012-05-31
CA2576190A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
JP2012102110A (ja) 造影剤の注入を受けるヒトの処置方法
Bataller et al. Hepatorenal syndrome
Rosenberger et al. Renal parenchymal oxygenation and hypoxia adaptation in acute kidney injury
Berg Nephrotoxicity related to contrast media
Neumayer et al. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial
Yu et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
Ansari et al. Acute renal failure due to radio-contrast agents
Meyrier Renal vascular lesions in the elderly: nephrosclerosis or atheromatous renal disease?
CN118477076A (zh) 用于治疗pik3ca相关过度生长综合征群的方法
Rudnick et al. Prevention of contrast-induced nephropathy
KR20220075329A (ko) 알콜성 간염의 치료
Evan et al. Renal disease potentiates the injury caused by SWL
Clark et al. Amelioration with vessel dilator of acute tubular necrosis and renal failure established for 2 days
Tanabe et al. Effects of collateral vessel occlusion on oral glucose tolerance test in liver cirrhosis
US20100266501A1 (en) Methods and compositions for organ protection
Laws et al. Intensification of chelating-therapy in patients with thalassemia major
RU2857200C2 (ru) Лекарственное средство dc009 для лечения острого ишемического инсульта
Andreucci et al. The renal problems in x-ray based imaging techniques using lodinated radiographic contrast agents
Couturier et al. WCN26-4317 Feasibility, benefit, and tolerance of free iron removal in pathological conditions
Nehme et al. Case Report of Intraoperative Anaphylactic Shock and Post-Operative Methemoglobinemia-Cetrimide induced during Hepatic Hydatid Cyst Surgery
Reimer Mangafodipir Trisodium “Teslascan”
JP2007001945A (ja) 癌治療剤
Dharnidharka et al. Role of radiological assessment and intervention in pediatric dialysis
JP2025014645A (ja) 急性腎障害の予防及び／又は治療薬
WO2026090251A1 (en) Methods for improving treatment outcomes in patients undergoing ultrafiltration

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110915

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120222